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Abstract 
In Europe and the United States, the recreational use of gamma- 
hydroxy butyric acid (GHB) at dance clubs and "rave" parties has 
increased substantially. In addition, GHB is used to assist in the 
commission of sexual assaults. The aim of this controlled clinical 
study was to acquire pharmacokinetic profiles, detection times, and 
excretion rates in human subjects. Eight GHB-na'ive olunteers 
were administered a single 25-mg/kg body weight oral dose of 
GHB, and plasma, urine, and oral fluid specimens were analyzed 
by using gas chromatography-mass spectrometry (GC-MS). 
Liquid-liquid extraction was performed after acid conversion of 
GHB to gamma-butyrolactone. Limits of quantitation of 0.1 (oral 
fluid), 0.2 (urine), and 0.5 pg/mL (plasma) could be achieved in the 
selected ion monitoring mode. GHB plasma peaks of 39.4 • 25.2 
pg/mL (mean • SEM) occurred 20-45 rain after administration. The 
terminal plasma elimination half-life was 30.4 • 2.45 rain, the 
distribution volume 52.7 • 15.0 L, and the total clearance 1228 • 
233 pL/min. In oral fluid, GHB could be detected up to 360 rain, 
with peak concentrations of 203 • 92.4 pg/mL in the 10-rain 
samples. In urine, 200 • 71.8 and 230 • 86.3 pg/mL, were the 
highest GHB levels measured at 30 and 60 rain, respectively. Only 
1.2 • 0.2% of the dose was excreted, resulting in a detection 
window of 720 rain. Common side-effects were confusion, 
sleepiness, and dizziness; euphoria and change of vital functions 
were not observed. GHB is extensively metabolized and rapidly 
eliminated in urine and oral fluid. Consequently, samples should be
collected as soon as possible after ingestion. 
Introduction 
Gamma-hydroxybutyric acid (GHB) is an endogenous com- 
pound present in most mammalian tissues at nanomolar 
concentrations and a minor metabolite or precursor f gamma- 
aminobutyric acid (GABA) (1-3). It has potential as a neuro- 
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transmitter and/or neuromodulator with binding to GABAB 
receptors. It is a weak agonist a GABAB. Recently, it has been 
shown that GHB also binds to a G-protein-coupled presynaptic 
receptor that is distinct from GABAB (4). GHB was first syn- 
thesized in 1960 by the French biochemist H.-M. Laborit who 
was searching for analogues of GABA (5). Later it was intro- 
duced in Europe as a sleep aid, to treat narcolepsy, and as a sur- 
gical anesthetic, but disappeared from the market because of 
insufficient anesthetic potency and unpredictable anesthetic 
duration. In the United States, GHB was freely available in 
health food stores and very popular in the body-builder com- 
munity as an anabolic steroid alternative. GHB was also used as 
a tryptophan replacement for weight control and sedation (6). 
The increasing abuse as a party drug, often together with 3,4- 
methylenedioxymethamphetamine (MDMA, Ecstasy) (7-10) 
and alcohol, and the use in crimes of drug-facilitated sexual as- 
saults ("date-rape drug") (1,11-14) resulted in the ban of GHB 
by the U.S. Food and Drug Administration (FDA) in the late 
1990s. At the recommendation of the World Health Organiza- 
tion (WHO), the Commission on Narcotic Drugs (CND) of the 
United Nations added GHB to Schedule IV of the 1971 Con- 
vention of Psychotropic Substances inMarch 2001. Since July 
2002, GHB is in the U.S. under the product name Xyrem | an 
approved rug for treatment ofcatalepsy associated with nar- 
colepsy (15). Inmost European countries, GHB is allowed only 
for research purposes or limited clinical use (e.g., as anesthetic 
adjuvant) (1). In view of the alcohol-mimicking effects on the 
central nervous ystem, GHB has also been tested in clinical 
practice for alcoholism management because it is very effective 
in suppressing the alcohol withdrawal syndrome and the fol- 
lowing alcohol craving (16). 
Gas chromatography (GC) with flame-ionization (11) or mass 
spectrometric (MS) detection (11,17-22) and capillary elec- 
trophoresis with IN or MS detection (9,23) have been used 
for GHB determination in biological fluids. Extraction can be 
performed by acidic onversion of GHB to gamma-butyrolac- 
tone (GBL) followed by liquid-liquid or solid-phase xtraction 
of GBL (20,21,23). Alternatively, GHBcan be analyzed without 
prior lactonization as the di-TMS derivative (17,18,22,24,25). 
Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. 625 
Journal of Analytical Toxicology, Vol. 28, November/December 2004 
Solid-phase microextraction (SPME) has also been used with 
subsequent detection of the hexyl derivative of GHB (19). 
The pharmacokinetics of GHB were studied in alcohol de- 
pendent (26) or narcoleptic patients (27); the dose-dependent 
absorption, elimination, and urinary excretion (single-subject 
study) were measured in healthy male volunteers (10,28). So 
far, no controlled clinical study was conducted where blood, 
urine, and oral fluid specimens were collected for analysis. 
Reviews of the history, pharmacology, clinical use, and anal- 
ysis of GHB have been published elsewhere (1-3,6). 
It was the aim of the present study to acquire pharmacoki- 
netic profiles of GHB and to compare its excretion in urine and 
oral fluids of eight GHB-nafve healthy volunteers after a single 
oral dose of 25 mg/kg body weight (b.wt.). In addition, psy- 
chological and somatic side-effects ofGHB were monitored. 
Experimental 
Materials 
GHB was supplied as the sodium salt (gamma-hydroxybu- 
tyrate, sodium oxybate) byFluka (Buchs, Switzerland) with a 
purity of 99.5% (HPLC). Gamma-valerolactone (GVL) was 
Table I. Limit of Detection, Limit of Quantitation, and 
Linearity of the GHB Determination in Different 
Matrices 
LOD LOQ ULOL Correlation 
(pg/mt) (pg/mL) (pg/mL) Coefficient (r2) t 
Plasma 0.2 0.5 200* 1.000 
Oral fluid 0.1 0.1 200 ~ 1.000 
Urine 0.1 0.2 900" 1.000 
* Maxinlunl (on( ~'nlr,llJon lesled. 
Based on a calibration curve from 10 to 50 H~mL. 
aquired from Sigma-Aldrich (St. Louis, MO). All other chemi- 
cals were of ACS analytical grade. 
Methods 
Subjects and clinical study. Eight healthy, GHB-na'fve vol- 
unteers (4 male, 4 female; 37 _+ 10 years old; 71 _+ 12 kg b.wt.; 
mean _+ sd) participated in the pharmacokinetic study, con- 
ducted at the Clinical Investigation Unit (CIU) of the University 
Hospital of Bern. The subjects were informed about he risks of 
the study and gave their written informed consent. The study 
was approved by the Regional Ethics Committee and the Swiss 
Agency for Therapeutic Products (Swissmedic). Each subject re- 
ceived a single oral dose of 25 mg GHB per kg b.wt. (1778 + 298 
mg) that was administered on an empty stomach as a freshly 
prepared solution of GHB sodium salt in water and by using a 
small drinking tube to avoid oral cavity contamination. The 
subjects were not allowed to consume any alcohol, drugs, or 
medications 48 h before, during, and for 24 h after the trial. 
Blood (10 mL) was collected through aperipheral vein catheter 
shortly before GHB dosing (baseline), and 10, 15, 20, 25, 30, 45, 
60, 90, 120, 150, 180, 240, and 360 min after dosing. The hep- 
arinized blood specimens were centrifuged for 10 min at 2000 
rpm, and the plasma samples instantly deep-frozen and stored 
at -20~ until analysis. Total urine was collected 10 min before 
and 120, 240, 360, 480, 720, and 1440 rain after dosing and 
stored at -20~ until analysis. Oral fluid, collected up to 360 
min using Sarstedt Salivettes (Sevelen, Switzerland), was cen- 
trifuged and stored at -20~ The pharmacodynamic easure- 
ments, performed at the blood sample collection times, 
consisted of monitoring vital functions (e.g., blood pressure, 
heart rate, hemoglobin oxygen saturation, etc.) and psycho- 
logical and somatic side-effects. 
Sample extraction. The extraction of GHB from 2 mL urine 
(clinical and calibration samples) was performed by adding 
50 1JL of the internal standard solution (GVL, 1.0 mg/mL) and 
0.5 mL of 20% trifluoroacetic a id to a 15-mL centrifuge tube. 
After vortex mixing, the tubes were capped and heated in an 
oven at 75~ for 1 h. The tubes were then removed from the 
Table II. Plasma Concentrations of GHB in GHB-Na'fve Subjects (n = 8) after an Oral Dose of 25 mg GHB per kg b.wt. 
Plasma concentration of GHB (pg/mt)* 
Time (min) 
Subject 0 10 15 20 25 30 45 60 90 120 150 180 240 360 
A < 0.2 0.82 1.72 5.23 10.4 31.3 23.3 18.1 2.46 ].19 0.89 0.70 < 0.2 < 0.2 
B < 0.2 0.52 0.25 0.56 0.86 0.62 1.45 1.25 3.05 4.70 2.36 1.02 0.66 1.30 
C <0.2 <0.2 10.8 8.58 7.17 9.71 16.9 12.1 9.94 3.32 1.84 <0.2 <0.2 <0.2 
D < 0.2 32.6 62.0 65.8 61.9 54.3 41.2 31.5 16.4 9.54 4.03 1.81 < 0.2 < 0.2 
E < 0.2 1.44 7.00 18.8 26.8 42.6 44.6 32.4 19.7 10.6 2.51 0.76 0.64 0.29 
F <0.2 6.30 11.0 16.2 21.4 18.2 11.5 8.92 4.05 2.50 1.52 0.58 <0.2 <0.2 
G < 0.2 19.2 30.5 41.4 56.2 52.7 33.7 22.9 10.2 1.45 < 0.2 < 0.2 < 0.2 <0.2 
H < 0.2 21.3 67.8 76.3 72.8 61.9 38.4 24.6 14.6 4.39 2.00 < 0.2 < 0.2 < 0.2 
Mean 10.3 23.9 29.1 32.2 33.9 26.4 19.0 10.1 4.71 1.89 
SEM 3.93 8.54 9.11 8.73 7.15 4.92 3.48 2.06 1.12 0.38 
* Quantitation of all values less than ] 0 pg/mL was based on a single-point calibration at I 0 pg/mL. 
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oven and allowed to cool down to room temperature. To each 
tube was then added 0.55 mL of 2M NaOH to adjust he pH to 
6.5 followed by 3 mL of chloroform. The tubes were capped and 
shaken for I rain. Approximately 0.5 mL of the organic layer 
(bottom) from each tube was transferred toa GC vial for injec- 
tion. 
The extraction procedure for plasma samples was the same as 
for urine except that 0.5 mL of plasma that was diluted with 1.5 
mL of deionized water before proceeding with the extraction 
process was used. 
The extraction oforal fluid samples was carried out by mea- 
suring 1 mL of the oral fluid from the collection device or 
whatever volume collected after centrifugation ofthe device and 
dilution with enough volume of deionized water to equal 
2 mL. The mixture was then extracted following the same pro- 
cedure as for urine. 
GC-MS analysis. An HP-5890 GC interfaced with an HP- 
5970B MSD operated in the selected ion monitoring (SIM) 
mode was used. Chromatographic separation was achieved on 
a J&W Scientific 25-m x 0.2-mm (0.33-1Jm film) DB-5 MS 
column operated from 60~ (1 min) to 90~ at 10~ the 
temperature was then raised to 270~ at 35~ with hold 
time of 1 min; oven equilibrium time was 0.5 min. Helium at 
a velocity of 38 cm/s was used as carrier gas. The electron mul- 
tiplier voltage was the same as the tune value. The injector 
100.0 i 
10.0 
30 60 00 120 t50 
Time (rain) 
Figure 1. Plasma profile of GHB after an oral dose of 25 mg GHB per kg 
b.wt., OHB-naive subjects (log of mean + SEM, n = 8). 
(250~ was operated in the splitless mode (split open at 0.2 
min), and 4 IJL of each sample was injected. Ions were moni- 
tored at m/z 42, 56, and 86 for GBL and 41, 56, and 85 for GVL. 
The retention times for GBL and GVL were 4.35 and 4.80 rain, 
respectively. Quantitation ofGBL was based on the peak area of 
the ion m/z 42 versus the peak area of the GVL ion m/z 56. 
Pharmacokinetic data analysis. Based on the non-compart- 
mental model, all pharmacokinetic parameters were assessed 
by use of standard calculation procedures performed by 
the TopFit Vers. 2.0 computer software. The linear trapezoidal 
rule was implemented for calculations of areas under the 
plasma concentration-time curves (AUC). The AUCs were 
extrapolated to infinity (AUC0 ~ ~) by adding the last quanti- 
tated concentration (at 360 min) divided by the elimination 
constant (kz). 
Results and Discussion 
The determination f GHB by GC-MS was performed after 
lactonization to GBL, followed by liquid-liquid extraction, w th 
GVL as the internal standard, resulting in a recovery of > 95%. 
A correlation coefficient r 2 of 1.000 was obtained for all cali- 
bration curves ofin the different matrices. The interday preci- 
sion of the GHB quantitation was + 8.7% determined with an 
8 ~g/mL control sample (n --- 12). The limit of detection (LOD), 
limit of quantitation (LOQ), and upper limit of linearity (ULOL) 
are given in Table I. 
After administration f a single oral dose of 25 mg GHB per 
kg b.wt. (1778 + 94.3 mg; mean • SEM) to 8 GHB-na'fve vol- 
unteers GHB plasma levels of < LOD (not detected) to 76.3 
IJg/mL (0.16 • 0.10 to 33.9 • 7.15 IJg/mL) were measured 
(Table II and Figure 1). Plasma peaks (Cmax) of 4.70 to 76.3 
IJg/mL (39.4 • 25.2 lag/mL), usually occurring between 20 and 
45 min, and the terminal plasma elimination half-lifes (tl/2z) of 
17.4 to 42.5 min (30.4 • 2.45 min) suggest that oral absorption 
and elimination of GHB are fast processes. The volume of dis- 
tribution (Vd) was 19.1 to 155 L (52.7 • 15.0 L), the mean res- 
idence time (MRT) 43.7 to 194 rain (73.2 • 15.7 min), and the 
total clearance (Cltot) 476 to 2520 mL/min (1228 • 233 
Table III. Pharmacokinetics of GHB in GHB-Na'ive Subjects (n = 8) after an Oral Dose of 25 mg GHB per kg b.wt. 
Subject 
A B C D E F G H Mean SEM 
Gender f f m m f f m m 
Body weight (kg) 58 64 89 80 61 59 80 78 71.1 3.77 
Dose (mg) 1450 1600 2225 2000 1525 1475 2000 1950 1778 94.3 
tma x (min) 30 120 45 20 45 25 25 20 41.3 10.6 
Cmax (pg/mL) 31.3 4.70 16.9 65.8 44.6 21.4 56.2 76.3 39.7 7.99 
AUC (pg*min/mL) 1330 635 1209 4043 3207 1114 2682 3622 2230 414 
MRT (rain) 54.2 194 66.4 54.3 71.0 56.0 43.7 45.6 73.2 15.7 
tl/2z (min) 17.4 42.5 32.4 33.1 36.8 30.5 26.0 24.6 30.4 2.45 
V d (L) 27.3 155 86.1 22.5 25.3 58.2 27.9 19.1 52.7 15.0 
Clto t(mL/min) 1090 2520 1840 495 476 1320 746 538 1128 233 
Urine recovery (%) 0.2 0.7 1.5 2.1 0.7 2.0 1.0 1.7 1.2 0.2 
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mL/min). Subject B displayed significantly higher MRT values 
(Vd and CI) than the other subjects. Liver and kidney functions 
were checked with this individual, were within e normal 
range, and thus did not explain the variation. The semilog plot 
of the plasma concentrations (Figure 1) shows linear elimina- 
tion kinetics. The pharmacokinetic data of GHB are summa- 
rized in Table III. 
As shown by Table IV and Figure 2,the GHB concentration in 
oral fluid varied between < LOD (not detected) and 778pg/mL 
(0.37 • 0.21 to 203 • 92.4 ug/mL). The highest values within a 
detection window f 360 min were usually observed in the 10- 
and 15-min samples. It cannot be excluded that the xtremely 
high levels of subject B and H at 10 and 15 min are due to a con- 
tamination by improper use of the drinking tube. No GHB 
could be detected in the baseline samples except subjects A 
and F. 
The GHB content in urine ranged from < LOD (not detected) 
to 840 IJg/mL (Table V and Figure 3). Peak concentrations 
varied remarkably between 22.4 and 8 0 ug/mL (257 • 82.2 
IJg/mL). With 230 • 86.3 IJg/mL, most subjects excreted th  
highest GHB concentrations in the 60-min urine. Recently it 
has been recommended to use a 104Jg/mL cutoff for the ap- 
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Figure 2. Oral fluid profile of GHB after an oral dose of25 mg GHB per 
kg b.wt., GHB-naYve subjects (mean +_. SEM, n = 8). 
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urinary GHB (29-31). Of the samples collected between 30 and 
720 min, 33% showed GHB levels < 10 pg/mL. However, no 
GHB (LOD = 0.1 pg/mL) could be detected in the baseline 
urine and in the specimens collected at the end of the study 
(1440 rain). The total amount of GHB recovered in urine within 
24 h was 3.16 to 41.6 mg (22.7 • 4.3 mg) corresponding to only 
0.2 to 2.1% (1.2 • 0.2%) ofthe dose administered. These data 
demonstrate the extensive metabolism of GHB. 
At the dose administered, GHB did not produce any severe 
psychotropic side-effects, nor were the vital functions signifi- 
cantly altered. Confusion and sleepiness were the main side-ef- 
fects observed. Less frequent was dizziness. 
Conclusions 
A pharmacokinetic study using GHB-naYve healthy subjects 
has revealed the extensive metabolism and rapid elimination of 
the drug in urine and oral fluids. The data indicate that there is 
a substantial interindividual variation among subjects in all 
three fluids collected. Only about 1% of the dose was recovered 
in urine, resulting in a detectability of 12 h. In oral fluid, the de- 
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Figure 3. Urine profile of GHB after an oral dose of 25 mg GHB per kg 
b.wt., GHB-naYve subjects (mean _+ SEM, n = 8). 
Table IV. Oral Fluid Concentrations of GHB in GHB-NaYve subjects (n = 8) after an Oral Dose of 25 mg GHB per kg b.wt. 
Oral Fluid Concentration of GHB (pg/mL)* 
Time (rain) 
Subject 0 10 15 20 25 30 45 60 90 120 150 180 240 360 
A 1.52 45.2 45.8 28.8 22.3 9.59 9.46 6.19 3.88 1.56 2.53 2.31 3.36 2.34 
B < 0.1 421 317 90.8 93.0 20.3 1.32 3.62 < 0.1 1.80 2.39 < 0.1 < 0.1 < 0.1 
C < 0.1 26.9 2.78 4.25 1.70 6.44 5.60 3.23 2.48 ].33 0.94 0.60 0.59 0.52 
D <0.1 <0.1 4.36 1.87 2.56 4.10 1.65 3.76 2.47 1.55 1.54 1.12 1.03 0.70 
E < 0.1 29.2 16.8 13.7 12.4 10.7 8.46 5.01 4.59 2.72 2.68 1.55 1.65 1.06 
F 1.40 2.27 < 0.1 5.78 0.71 < 0.1 < 0.1 2.30 0.77 0.65 ].03 0.78 1.61 1.46 
G < 0.1 118 48.3 15.4 10.7 8.85 3.68 3.04 3.68 1.00 1.25 1.22 1.20 1.99 
H < 0.1 778 269 48.5 36.1 25.9 8.99 12.4 2.49 1.69 2.14 < 0.1 1.21 0.88 
Mean 203 101 26.1 22.4 12.3 5.59 4.94 2.91 1.54 1.81 1.26 1.52 1.28 
SEM 92.4 42.2 9.59 9.78 2.49 1.10 1.03 0.40 0.19 0.22 0.19 0.28 0.22 
* Quantitation of all values less than 10 pg/mL was based on a single-point calibration at I 0 p~mL. 
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Table V. Urine Concentrations of GHB in GHB-Na'@e 
Subjects (n = 8) after an Oral Dose of 25 mg GHB per kg 
b.wt. 
Urine Concentration of GHB (pg/mL) 
Time (min) 
Subject 0 30 60 120 240 720 1440 
A <0.1 45.7 48.4 8.79 <0.1 <0.1 <0.1 
B <0.1 <0.1 15.6 111 20.5 3.24 <0.1 
C <0.1 184 232 129 53.1 2.56 <0.1 
D <0.1 654 840 311 13.8 4.96 <0.1 
E <0.1 5.01 22.4 18.4 8.19 <0.1 <0.1 
F <0.1 26.7 132 253 19.4 <0.1 <0.1 
G <0.1 181 194 62.7 25.4 < 0.1 < 0.1 
H <0.1 303 358 236 11.0 2.11 <0.1 
Mean 175 230 141 18.9 1.61 
SEM 70.1 86.3 35.9 5.04 0.60 
in as short time as possible from the time of ingestion. Re- 
cently, it has been demonstrated that a single exposure to GHB 
in a case of sexual assault can be documented by hair analysis 
when collected about one month after the crime (32). However, 
it is strongly advised to determine GHB basal levels (33). Con- 
centrations of < 10 pg/mL were observed in a significant 
number of specimens throughout he 1440-min collection pe- 
riod. This suggests that a recommended 10-pg/mL cutoff in 
urine (29-31) may be too high to be optimally sensitive for
forensic purposes. 
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